Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG, Petroni GR, Bauer T, Reilley MJ, Wolpin BM, Stucky CC, Bekaii-Saab TS, Elias R, Merchant N, Dias Costa A, Lenehan P, Cardot-Ruffino V, Rodig S, Pfaff K, Dougan SK, Nowak JA, Varadhachary GR, Slingluff CL, Rahma O. Katz MHG, et al. J Immunother Cancer. 2023 Dec 1;11(12):e007586. doi: 10.1136/jitc-2023-007586. J Immunother Cancer. 2023. PMID: 38040420 Free PMC article. Clinical Trial.
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.
Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB. Katz MH, et al. Ann Surg Oncol. 2010 Jul;17(7):1794-801. doi: 10.1245/s10434-010-0943-1. Epub 2010 Feb 17. Ann Surg Oncol. 2010. PMID: 20162463 Free PMC article.
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.
Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW; American College of Surgeons Oncology Group. Katz MH, et al. Ann Surg Oncol. 2011 Feb;18(2):337-44. doi: 10.1245/s10434-010-1282-y. Epub 2010 Sep 1. Ann Surg Oncol. 2011. PMID: 20811779 Free PMC article.
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Chatterjee D, et al. Cancer. 2012 Jun 15;118(12):3182-90. doi: 10.1002/cncr.26651. Epub 2011 Oct 25. Cancer. 2012. PMID: 22028089 Free PMC article.
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Zhao Q, et al. Ann Diagn Pathol. 2012 Jan;16(1):29-37. doi: 10.1016/j.anndiagpath.2011.08.005. Epub 2011 Nov 3. Ann Diagn Pathol. 2012. PMID: 22050964 Free PMC article.
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PW, Lee JE, Vauthey JN, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-Laly X, Charnsangavej C, Fleming JB. Katz MH, et al. J Gastrointest Surg. 2012 Jan;16(1):68-78; discussion 78-9. doi: 10.1007/s11605-011-1748-7. Epub 2011 Nov 8. J Gastrointest Surg. 2012. PMID: 22065318
362 results